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Introduction
Cirrhosis has two phases: a compensated phase 
with favorable prognosis and a decompensated 
phase with poor prognosis (median survival > 12 
years versus ~2 years, respectively).1,2 The shift 
from compensated to decompensated cirrhosis is 
characterized by the onset of complications, 
including ascites, hepatic encephalopathy (HE), 
varices and variceal bleeding, and spontaneous 
bacterial peritonitis (SBP),2–4 which are associ-
ated with substantial morbidity and mortality.5–12 
For patients with cirrhosis, the 30-day rehospi-
talization rate has been shown to increase with the 
number of cirrhosis-related complications, from 
11.1% with no complications to 24.3% with at 
least three complications.13 Ascites is the most 
common complication of cirrhosis.1 Occurrence 
of ascites is associated with mortality in 38% and 
78% of patients with cirrhosis after 2 and 5 years, 
respectively.14 Ascites is also associated with 
increased risk of developing other complications 
of cirrhosis, including hepatorenal syndrome, 
SBP, varices, and variceal bleeding.15–18
Hepatic encephalopathy is a neurologic complica-
tion of cirrhosis that affects 30–70% of patients.19,20 
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Abstract
Background: Cirrhosis-related complications are associated with poor prognosis. With our 
analyses, we examined the potential benefit of rifaximin in reducing the risk of developing 
cirrhosis-related complications.
Methods: Adults with cirrhosis and hepatic encephalopathy (HE) in remission were randomly 
assigned to receive rifaximin 550 mg twice daily or placebo for 6 months with concomitant 
lactulose permitted. Post hoc analyses examined time to cirrhosis-related complications (HE, 
spontaneous bacterial peritonitis (SBP), variceal bleeding, acute kidney injury/hepatorenal 
syndrome). Subgroup analyses evaluated efficacy for select baseline disease characteristics.
Results: Of patients receiving rifaximin (n = 140) and placebo (n = 159), 53.6% and 49.1%, 
respectively, had baseline Model for End-Stage Liver Disease (MELD) score ⩾ 12 and 
international normalized ratio (INR) ⩾ 1.2. Baseline ascites was observed in 36.4% (rifaximin) 
and 34.6% (placebo) of patients. In patients with MELD score ⩾ 12 and INR ⩾ 1.2, rifaximin 
reduced the relative risk (RR) of any first complication experienced during trial by 59% [hazard 
ratio (HR) = 0.41, 95% confidence interval (CI): 0.25–0.67; p < 0.001] versus placebo. For 
patients with baseline ascites, rifaximin reduced the RR of any first complication experienced 
during trial by 42% versus placebo (HR = 0.58, 95% CI: 0.34–1.0; p = 0.045). For some 
subgroups, there was a decrease in RR of complications of SBP, variceal bleeding, and acute 
kidney injury/hepatorenal syndrome with rifaximin versus placebo, although there were few 
events reported in the study.
Conclusion: Rifaximin may reduce the incidence of cirrhosis-related complications and the 
recurrence of overt HE.
[ClinicalTrials.gov identifier: NCT00298038.]
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Patients may present with symptoms that are not 
clinically apparent (minimal or covert HE; West 
Haven grade 1) or with more severe symptoms 
(overt HE; West Haven grades 2–4).20 For 
patients with cirrhosis who visit the emergency 
department, those with HE are at significantly 
greater risk of hospitalization compared with 
patients without HE [odds ratio (OR) = 4.4, 95% 
confidence interval (CI): 4.3–4.5; p < 0.01].21
The gut microbiota are thought to play a role in 
cirrhosis and development of cirrhosis-related 
complications.22,23 Intestinal permeability plays a 
role in the development of bacterial translocation 
and may be involved in the development of compli-
cations of cirrhosis; indeed, translocation of endo-
toxins is increased in patients with cirrhosis.24–27 
In a prospective study, patients with more 
severe cirrhosis (i.e. patients with decompensated 
cirrhosis, hospitalized patients) had signifi-
cantly greater serum endotoxin concentrations 
compared with patients with compensated cirrho-
sis (p < 0.0001), and a positive correlation between 
endotoxin concentration and the Model for End-
Stage Liver Disease [MELD; calculated using 
three laboratory parameters: the international nor-
malized ratio (INR), serum creatinine, and serum 
bilirubin]28 score was observed.29 Further, serum 
endotoxin concentrations were positively corre-
lated with the severity of HE in patients with cir-
rhosis in a single-center prospective study.30 Thus, 
it is apparent that endotoxins may mediate compli-
cations of cirrhosis, including HE.
Rifaximin is a nonsystemic antibiotic adminis-
tered as secondary prophylaxis for adults with cir-
rhosis and a history of overt HE.31 Rifaximin 
significantly decreased endotoxin concentrations 
from baseline in patients with cirrhosis after 
8 weeks (p = 0.02).32 In patients with cirrhosis 
and previous episodes of overt HE, rifaximin sig-
nificantly decreased the risk of recurrence of overt 
HE and overt HE-related hospitalization compared 
with placebo after 6 months of therapy (p < 0.001 
and p = 0.01, respectively).33 In a retrospective 
study of patients with cirrhosis, rifaximin in com-
bination with lactulose was associated with a sig-
nificantly decreased risk of mortality compared 
with lactulose alone [adjusted hazard ratio (HR) 
= 0.70; 95% CI: 0.51–0.95; p = 0.02].34 Further, 
during a median 18 months of follow-up, rifaxi-
min plus lactulose significantly decreased the risk 
of recurrence of overt HE and SBP compared 
with lactulose alone (overt HE: HR = 0.45, 95% 
CI: 0.28–0.71; p < 0.001; SBP: HR = 0.21, 95% 
CI: 0.11–0.41; p < 0.001).34
Cirrhosis and its complications (e.g. HE) have a 
substantial economic, social, and personal impact 
on affected patients, as well as their families and 
caregivers.35 Given that the number of primary 
prophylaxis treatments that prevent complica-
tions of cirrhosis is limited, it is important to 
examine whether rifaximin has the potential to 
reduce the risk of developing several complica-
tions of cirrhosis, including HE, SBP, variceal 
bleeding, and hepatorenal syndrome.36,37 Thus, 
the objective of the current analysis was to evalu-
ate the potential impact of rifaximin on the reduc-
tion of the risk of developing complications of 
cirrhosis (i.e. HE, SBP, variceal bleeding, acute 
kidney injury/hepatorenal syndrome) in patients 
with a history of overt HE. As the MELD score is 
often used to determine prognosis in patients 
with cirrhosis and help prioritize patients for liver 
transplantation,38,39 and the occurrence of ascites 
in patients with cirrhosis is associated with the 
subsequent development of other complications 
of cirrhosis (e.g. SBP, variceal bleeding, hepato-
renal syndrome),15–18 this post hoc analysis evalu-
ated the efficacy of rifaximin as prophylaxis for 
complications in patients with cirrhosis, based on 
baseline MELD/INR scores and the presence of 
ascites.
Methods
Patients and study design
Details of the patient population, inclusion and 
exclusion criteria, and study design have been 
published elsewhere.33 Briefly, adults with cirrho-
sis, history of ⩾ 2 episodes of overt HE (Conn 
score ⩾ 2) within 6 months of screening, but cur-
rently in remission from HE (i.e. Conn score 
⩽ 1), with a MELD score ⩽ 25 at study entry, 
were eligible for inclusion in the study. Exclusion 
criteria included active SBP or requirement of 
daily prophylactic therapy for SBP, renal insuffi-
ciency (serum creatinine > 2.0 mg/dl), anemia 
(hemoglobin < 8 g/dl), and hypovolemia or any 
electrolyte abnormality with the potential to 
affect mental function. The trial design was a 
randomized, phase III, placebo-controlled, multi-
center trial of rifaximin 550 mg (Xifaxan®, Salix 
Pharmaceuticals, Bridgewater, NJ, USA) or pla-
cebo administered twice daily (BID) for 6 months. 
Concomitant use of lactulose was permitted 
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during the study. As previously reported, the 
study protocol received approval by the institu-
tional review board or ethics committee at each 
center, and the study was conducted in adherence 
to guidelines from the International Conference 
on Harmonisation.33 All patients provided writ-
ten informed consent.
Assessments
Clinic visits occurred on days 7 and 14, and every 
2 weeks thereafter through day 168 (end of treat-
ment), with optional visits on days 42, 70, 98, 
126, and 154. The primary endpoint was time to 
a breakthrough episode of overt HE (i.e. an 
increase in Conn score from ⩽1 at baseline to 
⩾2, or an increase in Conn score and asterixis 
score of 1 grade for patients with a baseline Conn 
score of 0). Other common complications of cir-
rhosis (i.e. SBP, variceal bleeding, and acute kid-
ney injury/hepatorenal syndrome) were further 
analyzed post hoc by baseline disease severity char-
acteristics of MELD score, INR value, and pres-
ence of ascites. All complication events, except 
for HE, were collected from adverse event (AE) 
reporting (which included any discontinuation 
because of complications of cirrhosis). The inves-
tigator collected information on these AEs based 
on standard guidelines for diagnosing these events 
[i.e. abdominal ultrasound for ascites, endoscopy 
for detection of esophageal varices or variceal 
bleeding, and assessment of ascetic fluid (obtained 
by paracentesis)] for detection of SBP. The risk of 
complications of cirrhosis was compared in sub-
groups of patients with MELD scores ⩾ 12 and 
INR ⩾ 1.2 versus MELD scores < 12 and INR 
< 1.2, or in the presence or absence of ascites at 
baseline. For the subgroup analysis based on 
MELD/INR scores, a cutoff MELD score > 12 
was used because the original study only included 
patients with MELD score of ⩽ 25 and the 
median MELD score was 13.1 for rifaximin and 
12.4 for placebo. In addition, an INR of ⩾ 1.2 
threshold was used as an internal barometer to 
ensure that the MELD scores reflected liver func-
tion changes and to potentially avoid inclusion of 
patients with pre-existing primary renal dysfunc-
tion unrelated to cirrhosis.
Statistical analyses
The intent-to-treat (ITT) population included 
all patients randomly assigned to treatment 
who received at least one dose of study drug. 
Demographic and baseline characteristics were 
summarized using descriptive statistics. Time to 
the first episode, experienced during the trial, of 
breakthrough overt HE (primary efficacy end-
point) or other complications of cirrhosis (i.e. 
SBP, variceal bleeding, and acute kidney injury/
hepatorenal syndrome) for patients receiving 
rifaximin or placebo was analyzed using the Cox 
proportional hazards model, specifying a two-
sided test at a significance level of 0.05 under the 
proportional hazards assumption. For each treat-
ment group, Kaplan–Meier time-to-event meth-
ods were used to estimate the percentage of 
patients who experienced a breakthrough episode 
of overt HE on days 28, 56, 84, 140, and 168. 
Patients who completed the study without expe-
riencing a breakthrough episode of overt HE 
were censored at 6 months. Patients who discon-
tinued the study for other reasons (e.g. AE, 
patient request, liver transplantation) were con-
tacted 6 months after randomization to ascertain 
whether a breakthrough episode of overt HE or 
other outcome (e.g. mortality) had occurred.
Results
A total of 299 patients [rifaximin (n = 140), pla-
cebo (n = 159)] were included in the ITT popu-
lation.33 Demographic and baseline characteristics 
were generally comparable between groups 
(Table 1). Concomitant lactulose use during the 
study was reported by 91.4% and 91.2% of 
patients receiving rifaximin or placebo, respec-
tively. A comparable percentage of patients 
receiving rifaximin or placebo had a baseline 
MELD score ⩾ 12 and INR ⩾ 1.2 [53.6% 
(n = 75) versus 49.1% (n = 78)]. Approximately 
one third of patients in each treatment group had 
ascites present at baseline.
For patients with MELD scores ⩾ 12 and INR 
scores ⩾ 1.2, the HR for the time to any first 
complication of cirrhosis experienced during 
the trial for rifaximin (n = 75) versus placebo 
(n = 78) was 0.41, indicating a relative risk (RR) 
reduction of 59% with rifaximin during 6 months 
of treatment; p < 0.001 [Figure 1(a)].
Rifaximin was associated with a 68% reduction in 
the RR of developing overt HE during 6 months 
of treatment in patients with MELD scores ⩾12 
and INR scores ⩾1.2 (Table 2). There was a 
trend for reduction in the RR for overall non-
HE complications when event data were pooled 
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(i.e. SBP, variceal bleeding, and acute kidney 
injury/hepatorenal syndrome) in these patients 
(MELD scores ⩾ 12 and INR scores ⩾ 1.2); 
however, this reduction did not reach statistical 
significance [HR = 0.46, 95% CI: 0.18–1.17; 
p = 0.10; Figure 1(b)].
For patients with MELD scores <12 and INR 
scores <1.2, rifaximin reduced the RR of their 
first cirrhosis-related complication experienced 
during the trial by 74% during 6 months of treat-
ment [Figure 1(c)], although significance was not 
achieved (p = 0.06).
Patients with MELD scores <12 and INR scores 
<1.2 experienced low numbers of events, which 
made RR determination difficult for several indi-
vidual complications [HE (n = 10), acute kidney 
injury/hepatorenal syndrome (n = 1), varices, 
variceal bleeding, and gastrointestinal bleeding 
(n = 2), SBP (n = 0)]. However, rifaximin 
reduced the RR of overt HE for these patients 
during 6 months of treatment (87%) compared 
with placebo (Table 2).
For patients with ascites at baseline, rifaximin 
treatment during the trial was associated with a 
Table 1. Baseline demographics and disease characteristics.
Parameter Rifaximin
(n = 140)
Placebo
(n = 159)
Age, years, mean (SD) 55.5 (9.6) 56.8 (9.2)
Male sex, n (%) 75 (53.6) 107 (67.3)
Race, White, n (%) 118 (84.3) 139 (87.4)
Duration of current HE 
remission, days, mean 
(SD)
68.8 (47.7) 73.1 (51.3)
Time since advanced 
liver disease 
diagnosis, months, 
mean (SD)
51.2 (49.2) 60.5 (64.9)
MELD score, mean 
(SD)
13.1 (3.6) 12.7 (3.9)*
INR, mean (SD) 1.4 (0.3)$ 1.4 (0.4)‡
Ascites present, n (%) 51 (36.4) 55 (34.6)
 MELD ⩾12 and
INR ⩾1.2
MELD <12 and
INR <1.2
MELD ⩾12 and
INR ⩾1.2
MELD <12 and
INR <1.2
MELD score, mean 
(SD)*
15.4 (2.5) 8.0 (1.5) 15.7 (2.9) 7.9 (1.6)
INR, mean (SD)$‡ 1.6 (0.2) 1.1 (0.1) 1.6 (0.3) 1.1 (0.1)
 Ascites, yes Ascites, no Ascites, yes Ascites, no
MELD score, mean 
(SD)*
14.1 (3.7) 12.5 (3.5) 14.0 (4.2) 12.0 (3.6)
INR, mean (SD)$‡ 1.5 (0.3) 1.4 (0.3) 1.5 (0.3) 1.4 (0.4)
*n = 158 in placebo group.
$n = 130 in rifaximin group.
‡n = 147 in placebo group.
HE, hepatic encephalopathy; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; SD, standard 
deviation.
Table created from study data, with additional data from Bass et al.33
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42% decrease in the RR of experiencing their first 
cirrhosis complication during 6 months of treat-
ment versus placebo [Figure 2(a)].
For patients without ascites at baseline, rifaxi-
min treatment during the trial decreased the RR 
of their first cirrhosis complication by 61% ver-
sus placebo during 6 months of treatment 
[Figure 2(b)].
Further, rifaximin treatment for 6 months 
decreased the RR of overt HE by 48% and 68% 
in patients with and without baseline ascites, 
respectively (Table 2). Other complications of 
cirrhosis occurred in only a small number of 
patients, either with or without ascites at baseline 
(i.e. SBP, variceal bleeding, and acute kidney 
injury/hepatorenal syndrome; Table 2). While the 
reductions in complications appeared to be driven 
by the reduction in HE events, given the small 
number of non-HE events reported, a pooled 
analysis showed a 63% reduction in the RR of 
non-HE complications in patients with ascites at 
baseline, although significance was not achieved 
[HR = 0.37, 95% CI: 0.13–1.08, p = 0.06; 
Figure 2(c)].
No significant difference in the RR of non-HE 
complications was observed in patients without 
ascites at baseline [HR = 0.86, 95% CI: 0.26–
2.83; p = 0.81; Figure 2(d)].
In the subgroup of patients with ascites at base-
line, four patients experienced SBP events (all in 
the placebo group; p = 0.03), and in the subgroup 
of patients without ascites at baseline, three patients 
experienced SBP events (rifaximin, n = 2; 
placebo, n = 1). The onset of SBP AEs (n = 7 
overall) in this study ranged from 13 to 152 days, 
and only one patient (placebo group) had a his-
tory of SBP.
Discussion
In the treatment of patients with cirrhosis, pro-
phylactic agents are needed to reduce the over-
all risk of complications. Given the role of the 
INR-driven MELD score in determining prog-
nosis in patients with cirrhosis38 and that the 
presence of ascites is associated with the subse-
quent development of other complications of 
cirrhosis (e.g. SBP, variceal bleeding, hepatore-
nal syndrome),15–18 this post hoc analysis evalu-
ated the efficacy of rifaximin 550 mg BID for 
6 months as prophylaxis of complications in 
patients with cirrhosis, based on baseline INR, 
MELD score, and presence of ascites.
During 6 months of treatment, rifaximin 
decreased the RR of any first complication of 
cirrhosis experienced during the trial for patients 
with MELD score ⩾ 12 and INR ⩾ 1.2, com-
pared with placebo. Similarly, rifaximin decreased 
the RR of any first complication of cirrhosis in 
Figure 1. Time to a first complication of cirrhosis 
experienced during the trial by treatment group and 
baseline disease severity.
(a) All complications of cirrhosis in patients with MELD 
score ⩾ 12 and INR ⩾1.2; (b) non-HE complications of 
cirrhosis in patients with MELD score ⩾ 12 and INR ⩾ 1.2; 
and (c) all complications of cirrhosis in patients with MELD 
score <12 and INR <1.2.
BID, twice daily; CI, confidence interval; HE, hepatic 
encephalopathy; HR, hazard ratio; INR, international 
normalized ratio; MELD, Model for End-Stage Liver Disease.
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patients with and without baseline ascites. 
Findings in these subgroups were driven by the 
inclusion of HE in the analysis. A separate pooled 
analysis that excluded HE found a trend in RR 
reduction with rifaximin in either MELD sub-
group that did not reach statistical significance, 
potentially because non-HE complications were 
experienced by only a few patients. Not unex-
pectedly for the complication of HE, rifaximin 
significantly reduced the RR of its recurrence in 
both MELD subgroups and both ascites sub-
groups during 6 months of treatment.
In this current study, the number of patients in all 
subgroups who experienced individual complica-
tions of cirrhosis other than HE (i.e. SBP, variceal 
bleeding, acute kidney injury/hepatorenal syn-
drome) was small. Although the data from this 
study do not unequivocally show that rifaximin 
reduces the rate of non-HE complications of 
cirrhosis, a trend in RR reduction was observed 
that did not reach statistical significance, con-
ceivably related to the small number of events. 
Thus, this warrants examining the occurrence of 
non-HE-related events in future studies, with 
larger patient populations, that are appropriately 
powered. However, results from another study 
have shown that patients receiving rifaximin had 
significantly decreased incidence of acute kidney 
injury and hepatorenal syndrome compared 
with patients not receiving rifaximin (p = 0.02 
and p = 0.01, respectively).40 Likewise, in the 
current study, rifaximin was associated with a RR 
reduction for incidence of SBP compared with 
placebo in the subgroup of patients with ascites at 
baseline; however, the number of patients experi-
encing SBP in this study was small (n = 7 over-
all). Consistent with this finding, a separate 
retrospective medical records review reported 
that patients receiving rifaximin for the primary 
prevention of SBP had a 72% decrease in the risk 
of occurrence of SBP compared with patients not 
receiving rifaximin (HR = 0.28, 95% CI: 0.11–0.71; 
p = 0.007).36 A second retrospective review of 
421 patients with cirrhosis found that 6.8% and 
42.7% of patients receiving rifaximin 600 mg 
BID plus lactulose or lactulose alone, respec-
tively, for a median 18 months experienced SBP; 
rifaximin plus lactulose decreased the risk of 
developing SBP by 79% compared with lactulose 
Figure 2. Time to a first complication of cirrhosis experienced during the trial by treatment group.
All complications of cirrhosis according to (a) presence or (b) absence of ascites at baseline; and non-HE complications of 
cirrhosis according to (c) presence or (d) absence of ascites at baseline.
BID, twice daily; CI, confidence interval; HE, hepatic encephalopathy; HR, hazard ratio.
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alone.34 In the current study, although the num-
ber of events was low overall, fewer patients with 
ascites and fewer patients with MELD ⩾ 12 and 
INR ⩾ 1.2 receiving rifaximin experienced SBP 
compared with those receiving placebo. Another 
randomized study, which compared rifaximin 
and norfloxacin for the prevention of SBP in 
patients with cirrhosis and ascites, reported that 
significantly fewer patients who received rifaxi-
min 400 mg three times daily for 6 months expe-
rienced SBP compared with those who received 
norfloxacin (3.9% versus 14.1%, respectively; 
p = 0.04).41 However, another study of patients 
with cirrhosis-related ascites reported that rifaxi-
min did not exhibit greater efficacy for the pre-
vention of SBP compared with systemic 
antibiotics (incidence of 30% versus 0%, respec-
tively).42 Future larger prospective studies are 
warranted to examine whether rifaximin has the 
potential to decrease the risk of SBP, given the 
association of SBP with HE, hospitalization, and 
mortality.17,43,44
The post hoc nature of the current analysis is a 
limitation, as the trial was powered for preven-
tion of complications of overt HE and was not 
powered to examine the efficacy of rifaximin for 
prevention of all complications or other individ-
ual complications of cirrhosis (e.g. SBP). In 
addition, only patients with a baseline MELD 
score ⩽ 25 were included in this study, hence, 
excluding patients with more severe disease. 
Further, the study was designed to assess rifaxi-
min as secondary prophylaxis for overt HE and 
included patients who experienced at least two 
episodes of HE in the previous 6 months. 
Whether the number of baseline episodes of HE 
may have impacted the development of future 
episodes or other complications of cirrhosis 
remains unclear. However, a post hoc analysis of 
a 24-month, open-label study examining rifaxi-
min efficacy in the prevention of recurrence of 
overt HE that included both patients from the 
current study and newly enrolled patients indi-
cated that there was an association between the 
number of previous episodes of HE reported at 
baseline and an increased risk of additional epi-
sodes, particularly for patients with baseline 
MELD scores ⩽ 10.45 In addition, non-HE 
complications of cirrhosis events were collected 
as part of the AE reporting in this analysis by the 
investigating physician, based on standard 
guidelines for diagnosing these events. Lastly, 
the current analysis was restricted to 6 months 
of treatment, and thus the potential long-term 
impact of rifaximin on preventing the complica-
tions of cirrhosis remains to be elucidated.
Conclusions
Rifaximin 550 mg BID for 6 months reduced 
the incidence of complications of cirrhosis and 
the recurrence of overt HE in patients with 
more severe cirrhosis (i.e. MELD score ⩾ 12 
and INR ⩾ 1.2 versus MELD score < 12 and 
INR < 1.2) and in patients with baseline ascites. 
Further research on the potential role of rifaxi-
min as prophylaxis against the complications of 
cirrhosis and HE in larger, prospective studies is 
warranted.
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